trending Market Intelligence /marketintelligence/en/news-insights/trending/9ty3e6GRk1BEpI_Mg0xbDQ2 content esgSubNav
In This List

US FDA approves Acorda's Parkinson's treatment

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA approves Acorda's Parkinson's treatment

Ardsley, N.Y.-based Acorda Therapeutics Inc. said the U.S. Food and Drug Administration approved its Parkinson's treatment Inbrija.

Inbrija is a formulation of one of the main drugs used to treat Parkinson's — levodopa. It will be used in patients experiencing so-called off periods, when the effects of an existing medication start to wear off in between doses, or the re-emergence of Parkinson's symptoms.

Acorda's medicine will be commercially available during the first quarter of 2019.